Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3428]

Novel PET tracers and their future use in assessment of response to treatment

Dr Andrei Iagaru – Stanford University, CA, USA

Novel PET tracers and their future use in assessment of response to treatment ( Dr Andrei Iagaru – Stanford University, CA, USA )

Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in...

Prof Max Topp - University of Wuerzberg, Germany

$Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in patients with refractory disease ( Prof Max Topp - University of Wuerzberg, Germany )$

Treating metastatic melanoma with vemurafenib

Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA

Treating metastatic melanoma with vemurafenib ( Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA )

Clinical trials for rare tumour types

Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA

Clinical trials for rare tumour types ( Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA )

First line treatment against metastatic breast cancer

Dr Karen Gelmon – BC Cancer Agency, Vancouver, Canada

First line treatment against metastatic breast cancer ( Dr Karen Gelmon – BC Cancer Agency, Vancouver, Canada )

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma

Dr Sagar Lonial – Emory University, Atlanta, USA

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma ( Dr Sagar Lonial – Emory University, Atlanta, USA )

Effects of panitumumab against oesophageal-gastro cancer and carcinomas

Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK

Effects of panitumumab against oesophageal-gastro cancer and carcinomas ( Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK )

Effects of lapatinib and trastuzumab on progression free survival

Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA

Effects of lapatinib and trastuzumab on progression free survival ( Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA )

ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma

Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias...

ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias Rummel - University Hospital Giessen, Germany )

President's overview of ASCO 2012

Dr Michael Link - Stanford School of Medicine, California, USA

President's overview of ASCO 2012 ( Dr Michael Link - Stanford School of Medicine, California, USA )

Drug shortage impact on cancer care and efforts to resolve the issue

Dr Sandra Kweder - US Food and Drug Administration

Drug shortage impact on cancer care and efforts to resolve the issue ( Dr Sandra Kweder - US Food and Drug Administration )

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma

Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma ( Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany )

More from ecancer